前列舒通+喹诺酮类抗菌药物治疗ⅢA型前列腺炎的效果观察

Observation on the Efficacy of Proloxone Combined with Quinolone Antimicrobial Drugs in the Treatment of Type Ⅲ A Prostatitis

目的:探讨前列舒通联合喹诺酮类抗菌药物治疗ⅢA型前列腺炎的临床效果。方法:在郑州人民医院2015年12月至2017年10月期间诊治的ⅢA型前列腺炎患者中选取96例作研究对象,并按治疗方案不同予以分组:对照组(n=48)常规使用喹诺酮类抗菌药物治疗,研究组(n=48)则采取前列舒通联合喹诺酮类抗菌药物治疗,就2组患者整体疗效以及治疗前后中医证候积分、生活质量水平进行统计学分析。结果:(1)研究组患者的整体治疗有效率是97.92%,与对照组患者的整体治疗有效率83.33%相比较高(P<0.05);(2)治疗前,研究组和对照组的中医证候积分比较无统计学差异(P>0.05);治疗后,2组患者中医证候积分均降低,其中研究组更低于对照组(P<0.05);(3)治疗前,2组患者的生活质量评分比较无统计学差异(P>0.05);治疗后,2组患者生活评分均高于治疗前(P<0.05),其中研究组更高(P<0.05)。结论:前列舒通联合喹诺酮类抗菌药物治疗ⅢA型前列腺炎的临床效果肯定,值得推广。

Objective:To investigate the clinical effect of antiseptic drugs combined with proloxone in the treatment of typeⅡA prostatitis.Methods:96 patients with typeⅢA prostatitis treated in the hospital between December 2015 and October 2017 were selected and grouped according to the treatment plan:the control group(N=48)was routinely treated with quinolone antimicrobial drugs.The research group(N=48)took the treatment of the antiseptic drugs of the proloxutone and quinolone,and conducted a statistical analysis of the overall efficacy of the two groups of patients,as well as the syndromes points and quality of life levels before and after treatment.Results:The overall treatment efficiency of the patients in the study group was 97.92%,which was higher than the total treatment efficiency of 83.33%of the patients in the control group(P 0.05);Before the treatment,there was no statistical difference in TCM syndromes between the group and the control group(P>0.05);After treatment,the TCM score of the two groups of patients was reduced,and the research group was lower than the control group(P 0.05);Before the treatment,there was no statistical difference in the quality of life score of the two groups(P>0.05);After treatment,the life score of the two groups was higher than that before treatment(P 0.05),and the study group was higher(P 0.05).Conclusion:The clinical effect of antiseptic drugs combined with aleolastomide and quinolone in the treatment of typeⅢA prostatitis is positive and worthy of promotion.